Primary Myelofibrosis (DIPSS-Plus stratified) · Allogeneic hematopoietic cell transplant for high-risk PMF
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-ALLOHCT-PMF |
| ID | IND-PMF-ALLOHCT-HIGH-RISK |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PMF |
| Sources | SRC-DIPSS-PLUS-GANGAT-2011 SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track for high-risk PMF transplant-eligible. JAKi pre-HCT bridging standard. Ukraine: limited transplant centers; international referral common.
Used By
Algorithms
ALGO-PMF-2L- ALGO-PMF-2L